SecBot SecBot
8-K ·Filed Nov 5, 2026

EVH

Evolent Health, Inc.
NEUTRAL
Impact 5/10
Horizonweeks Processed11d 18h ago SEC0001628908-26-000102
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

Revenue growth is strong from new oncology contracts, but the rising medical expense ratio (93.0% vs 85.0%) and declining Adjusted EBITDA margin signal cost pressure. The raised EBITDA guidance suggests management expects margin improvement in Q4. Monitor the MER trajectory and cash flow conversion in the next quarter.

DirectionNeutral
Confidencehigh
Horizonweeks

Price Chart

Loading chart...

Executive Summary

Evolent Health reported Q3 2026 revenue of $725.4M, up 51% YoY, and a GAAP net loss of $23.6M, narrower than the $26.9M loss a year ago. The company reiterated its 2026 revenue guidance of $2.6B-$2.7B and raised its Adjusted EBITDA guidance to $130M-$135M, signaling improved profitability expectations.

Key Financial Metrics

EPS (Adj.)
$0.06
est $0.06 · 0.0% · GAAP: $-0.21
Revenue
$725.4M
est $727.1M · -0.2% · +51.2% YoY
Rating
in line
Guidance
$2.6B-$2.7B
raised

Key Facts

  • Q3 2026 revenue of $725.4M, up 51% from $479.5M in Q3 2025
  • GAAP net loss of $23.6M vs $26.9M loss in Q3 2025
  • Adjusted EBITDA of $34.3M vs $39.0M in Q3 2025; margin 4.7% vs 8.1%
  • Medical Expense Ratio (MER) worsened to 93.0% from 85.0% a year ago
  • Performance Suite revenue grew to $564.3M from $286.9M, driven by oncology launches
  • Full year 2026 revenue guidance reiterated at $2.6B-$2.7B
  • Full year 2026 Adjusted EBITDA guidance raised to $130M-$135M from $120M-$135M
  • Cash and cash equivalents of $148.3M as of September 30, 2026

Financial Impact

Revenue grew 51% YoY to $725.4M; Adjusted EBITDA margin compressed to 4.7% from 8.1%; MER rose to 93.0% from 85.0%

revenuenet lossadjusted EBITDAmedical expense ratio

Segment Breakdown

SegmentRevenueGrowth
Performance Suite$564.3M+96.7%
Specialty Technology and Services Suite$72.8M-21.9%
Administrative Services$48.3M-16.5%
Cases$40.0M-3.8%

Risk Factors

  • Medical Expense Ratio increased to 93.0% from 85.0%, indicating higher claims costs
  • Adjusted EBITDA margin declined to 4.7% from 8.1% despite revenue growth
  • Net loss continues, though narrowed year-over-year
  • High leverage with $969.5M in long-term debt against $372.9M in equity

Market Snapshot

Exchange
NYSE
Sector
Services-Management Services
Analyst Consensus
78% bullish (18 analysts)

Investment Themes

Services

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001628908-26-000102
Document: evh-20261105.htm0001628908-26-000102
Document: 0001628908-26-000102-index-headers.html0001628908-26-000102
Document: 0001628908-26-000102-index.html0001628908-26-000102
Document: 0001628908-26-000102.txt0001628908-26-000102
8-K Data (Synthetic)0001628908-26-000102

US Market Status

Market Closed · Opens in 7h 55m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 5, 2026